Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.47 |
| ▸ | RARA | P10276 | 2/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 9/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16534058 | 0.82 | RARB (0.60) | AXLRARBRARARARGKDM4E | |
| SCHEMBL30641680 | 0.82 | RARB (0.60) | AXLRARBRARARARGKDM4E | |
| SCHEMBL1952898 | 0.82 | ALOX5AP (0.53) | FEN1ALOX5AP | |
| SCHEMBL17177744 | 0.79 | RARB (0.57) | AXLRARBRARARARGKDM4E | |
| SCHEMBL29372732 | 0.79 | RARB (0.57) | AXLRARBRARARARGKDM4E | |
| SCHEMBL1949865 | 0.79 | ALOX5AP (0.50) | FEN1ALOX5AP | |
| SCHEMBL16609011 | 0.77 | RARB (0.55) | AXLRARBRARARARGKDM4E | |
| SCHEMBL29784185 | 0.77 | RARB (0.55) | AXLRARBRARARARGKDM4E | |
| SCHEMBL16681332 | 0.76 | MAPK1 (0.46) | AXLRARBRARARARGSLC22A12 | |
| SCHEMBL1951514 | 0.76 | FEN1 (0.52) | FEN1ALOX5APKDM4EMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE HOLDINGS CORPORATION | 2020-10-08 | — | — | US | disclosed |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3443958-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2018-10-04 | — | — | US | disclosed |
| EP-3034075-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9944645-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2497470-B1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORP (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20130324515-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8461330-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2099447-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORP (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2497470-A1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | AXL 89/4885RARB 1261/4885RARA 1706/4885 |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | AXL 71/4885RARB 983/4885RARA 1223/4885 |
| US-20130324515-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | AXL 89/4885RARB 1261/4885RARA 1706/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | AXL 89/4885RARB 1261/4885RARA 1706/4885 |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | AXL 71/4885RARB 983/4885RARA 1223/4885 |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | AXL 89/4885RARB 1261/4885RARA 1706/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | AXL 89/4885RARB 1261/4885RARA 1706/4885 |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | AXL 71/4885RARB 983/4885RARA 1223/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | AXL 89/4885RARB 1261/4885RARA 1706/4885 |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | AXL 71/4885RARB 983/4885RARA 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.